Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
旗舰先锋和隐喻生物技术公司宣布与诺和诺德合作开发下一代肥胖管理疗法，诺和诺德可能支付高达6亿美元的预付款、开发和商业里程碑款项
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
旗舰先锋和隐喻生物技术公司宣布与诺和诺德合作开发下一代肥胖管理疗法，诺和诺德可能支付高达6亿美元的预付款、开发和商业里程碑款项
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。